• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Cogent Biosciences (COGT) Files FDA Application As Bezuclastinib Hype Meets A Pricey Valuation

    Simply Wall St·07/10/2026 13:35:40
    Listen to the news

    Cogent Biosciences (COGT) is back in focus after submitting a New Drug Application to the FDA for bezuclastinib in Advanced Systemic Mastocytosis, supported by positive response rates and safety data from the pivotal APEX trial.

    See our latest analysis for Cogent Biosciences.

    At a share price of $40.51, Cogent Biosciences has seen momentum build recently, with a 26.67% 1 month share price return and a 273.36% 1 year total shareholder return, set against index removals in late June and the bezuclastinib NDA submission now in focus.

    If this kind of biotech catalyst has your attention, it could be a good moment to scan for other potential opportunities through the 40 healthcare AI stocks

    The sharp move in Cogent Biosciences after the bezuclastinib NDA and index removals could signal a reset around the underlying AdvSM opportunity, or simply a swing in sentiment. How does the current valuation reflect that trade off?

    Price to Book of 12.8x: Is It Justified?

    Cogent Biosciences currently trades on a P/B of 12.8x, which sits well above both its biotech peers and the wider US Biotechs industry, so the recent share price strength already embeds a rich valuation on this yardstick.

    The P/B ratio compares the market value of the equity to the accounting book value, which can be a useful reference point when a company like Cogent Biosciences has minimal current revenue and is still loss making. In this case, the market is putting a sizeable premium on the company’s asset base and pipeline relative to peers.

    According to the checks provided, Cogent Biosciences is described as expensive versus its direct peer average P/B of 12.3x, and even more so versus the broader US Biotechs industry average of 2.8x. That is a wide gap and it suggests investors are already paying a higher multiple than both close comparables and the typical biotech stock for exposure to the bezuclastinib program and the rest of the pipeline.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 12.8x (OVERVALUED)

    However, the Cogent Biosciences story still carries clear risks, including a clinical or regulatory setback for bezuclastinib and future funding needs while the company remains loss making.

    Find out about the key risks to this Cogent Biosciences narrative.

    Next Steps

    If the mixed signals on Cogent Biosciences have you weighing both optimism and caution, now is a good time to check the data directly and sharpen your own view by looking at the 1 key reward and 2 important warning signs.

    Looking for more investment ideas beyond Cogent Biosciences?

    Once you have formed a view on Cogent Biosciences, do not stop there. Broaden your watchlist with focused stock ideas that match your investing style.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.